Fenwick & West represented MRL Ventures Fund, the strategic life sciences investment arm of Merck & Co., Inc. that is focused on innovative therapeutics companies developing transformative medicines, in Lava Therapeutics’ EUR 16 million financing round, raised from an investor syndicate led by Gilde Healthcare and Versant Ventures with additional support from U.S.-based MRL Ventures and founding investors Lupus Ventures and Biox Biosciences.

The funding will support development of LAVA’s proprietary pipeline of bispecific gamma-delta (γδ) T cell engagers for the treatment of cancer. More information regarding MRL Ventures’ participation in Lava’s financing can be obtained from the company announcement​.

The Fenwick transaction team was led by corporate partner Ian Goldstein and of counsel Brian Hicks.

Login

Don’t have an account yet?

Register